Brad Edwards has been confirmed as general manager Australia and New Zealand of the merged Shire and Baxalta.
Mr Edwards has been general manager of Shire's Australian and New Zealand business since January 2014.
Shire recently completed its US$32 billion acquisition of Baxalta, creating a global biotechnology company expected to generate annual revenues in excess of US$20 billion by 2020.
The companies are understood to have kicked-off their local integration in early June, with the aim of completing the process by early September. The new Shire will have double the number of employees and twice the revenue.
Heath Merlo, the former head of Baxalta's Australian operation, will remain with the new company, taking up a position as regional marketing Head for Asia Pacific.
Shire has grown its product portfolio in Australia to include treatments across a diverse range of conditions, including Fabry and Gaucher Disease, Hyperphosphatemia Hereditary Angiodema, Attention Deficit Hyperactivity Disorder and Ulcerative Colitis.
The combination with Baxalta extends Shire's product portfolio into Haemophilia, Immunology and Oncology areas.
On completion of the acquisition, Shire CEO Dr Flemming Ornskov said the company “is now the global leader in rare diseases, with the number one rare diseases platform based on both revenue and pipeline programs."